Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PF-03446962, a fully-human monoclonal antibody against transforming growth-factor β (TGFβ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial.
Necchi A, Giannatempo P, Mariani L, Farè E, Raggi D, Pennati M, Zaffaroni N, Crippa F, Marchianò A, Nicolai N, Maffezzini M, Togliardi E, Daidone MG, Gianni AM, Salvioni R, De Braud F. Necchi A, et al. Among authors: pennati m. Invest New Drugs. 2014 Jun;32(3):555-60. doi: 10.1007/s10637-014-0074-9. Epub 2014 Feb 26. Invest New Drugs. 2014. PMID: 24566706 Clinical Trial.
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Necchi A, et al. Among authors: pennati m. Lancet Oncol. 2012 Aug;13(8):810-6. doi: 10.1016/S1470-2045(12)70294-2. Epub 2012 Jul 20. Lancet Oncol. 2012. PMID: 22819172 Clinical Trial.
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Necchi A, et al. Among authors: pennati m. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14. Br J Cancer. 2014. PMID: 24231947 Free PMC article. Clinical Trial.
Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial.
Necchi A, Lo Vullo S, Giannatempo P, Raggi D, Calareso G, Togliardi E, Crippa F, Pennati M, Zaffaroni N, Perrone F, Busico A, Colecchia M, Nicolai N, Mariani L, Salvioni R. Necchi A, et al. Among authors: pennati m. Ann Oncol. 2017 Jun 1;28(6):1346-1351. doi: 10.1093/annonc/mdx124. Ann Oncol. 2017. PMID: 28383677 Free article. Clinical Trial.
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Necchi A, Lo Vullo S, Raggi D, Perrone F, Giannatempo P, Calareso G, Togliardi E, Nicolai N, Piva L, Biasoni D, Catanzaro M, Torelli T, Stagni S, Colecchia M, Busico A, Pennati M, Zaffaroni N, Mariani L, Salvioni R. Necchi A, et al. Among authors: pennati m. Urol Oncol. 2018 Jan;36(1):8.e1-8.e8. doi: 10.1016/j.urolonc.2017.08.020. Epub 2017 Sep 12. Urol Oncol. 2018. PMID: 28911922 Clinical Trial.
Survivin as a target for new anticancer interventions.
Zaffaroni N, Pennati M, Daidone MG. Zaffaroni N, et al. Among authors: pennati m. J Cell Mol Med. 2005 Apr-Jun;9(2):360-72. doi: 10.1111/j.1582-4934.2005.tb00361.x. J Cell Mol Med. 2005. PMID: 15963255 Free PMC article. Review.
Targeting survivin in cancer therapy.
Pennati M, Folini M, Zaffaroni N. Pennati M, et al. Expert Opin Ther Targets. 2008 Apr;12(4):463-76. doi: 10.1517/14728222.12.4.463. Expert Opin Ther Targets. 2008. PMID: 18348682 Review.
60 results